627 related articles for article (PubMed ID: 21453683)
1. Recent advances in the development of coagulation factors and procoagulants for the treatment of hemophilia.
Schaub RG
Biochem Pharmacol; 2011 Jul; 82(2):91-8. PubMed ID: 21453683
[TBL] [Abstract][Full Text] [Related]
2. Coagulation factors with improved properties for hemophilia gene therapy.
Pipe SW
Semin Thromb Hemost; 2004 Apr; 30(2):227-37. PubMed ID: 15118934
[TBL] [Abstract][Full Text] [Related]
3. Progress in the treatment of bleeding disorders.
Bergman GE
Thromb Res; 2011 Jan; 127 Suppl 1():S3-5. PubMed ID: 21035836
[TBL] [Abstract][Full Text] [Related]
4. Pioneering designs for recombinant coagulation factors.
Schulte S
Thromb Res; 2011; 128 Suppl 1():S9-12. PubMed ID: 22221848
[TBL] [Abstract][Full Text] [Related]
5. Plasma derivatives: new products and new approaches.
Sauna ZE; Pandey GS; Jain N; Mahmood I; Kimchi-Sarfaty C; Golding B
Biologicals; 2012 May; 40(3):191-5. PubMed ID: 22239993
[TBL] [Abstract][Full Text] [Related]
6. Inhibitor antibodies to factor VIII and factor IX: management.
Lusher JM
Semin Thromb Hemost; 2000; 26(2):179-88. PubMed ID: 10919411
[TBL] [Abstract][Full Text] [Related]
7. [New approaches to haemophilia treatment--recombinant and transgenic concentrates, gene therapy and engineered coagulation factors].
Habart D
Cas Lek Cesk; 2006; 145(2):104-11. PubMed ID: 16521398
[TBL] [Abstract][Full Text] [Related]
8. Treatment of patients with factor VIII and factor IX inhibitors with special focus on the use of recombinant factor VIIa.
Hedner U
Thromb Haemost; 1999 Aug; 82(2):531-9. PubMed ID: 10605747
[No Abstract] [Full Text] [Related]
9. Hemophilia. Strategies for the treatment of inhibitor patients.
Ingerslev J
Haematologica; 2000 Oct; 85(10 Suppl):15-20. PubMed ID: 11187863
[TBL] [Abstract][Full Text] [Related]
10. The promise and challenges of bioengineered recombinant clotting factors.
Pipe SW
J Thromb Haemost; 2005 Aug; 3(8):1692-701. PubMed ID: 16102035
[TBL] [Abstract][Full Text] [Related]
11. Recombinant factor VIII in hemophilia A: the Canadian experience.
Blanchette VS
Blood Coagul Fibrinolysis; 1997 Aug; 8 Suppl 1():S33-9. PubMed ID: 9351535
[TBL] [Abstract][Full Text] [Related]
12. Advances in clotting factor treatment for congenital hemorrhagic disorders.
Tarantino MD; Aledort LM
Clin Adv Hematol Oncol; 2004 Jun; 2(6):363-8. PubMed ID: 16163206
[TBL] [Abstract][Full Text] [Related]
13. [Revision consensus hemophilia: treatment and responsibility. Nederlandse Vereniging van Hemophilia Patients].
Briët E; Mauser-Bunschoten EP
Ned Tijdschr Geneeskd; 1997 Dec; 141(52):2566-71. PubMed ID: 9555158
[TBL] [Abstract][Full Text] [Related]
14. The role of plasma-derived factor VIII/von Willebrand factor concentrates in the treatment of hemophilia A patients.
Auerswald G; Spranger T; Brackmann HH
Haematologica; 2003 Jun; 88(6):EREP05. PubMed ID: 12826531
[TBL] [Abstract][Full Text] [Related]
15. Thrombin generation and fibrinolysis in anti-factor IX treated blood and plasma spiked with factor VIII inhibitor bypassing activity or recombinant factor VIIa.
Bolliger D; Szlam F; Molinaro RJ; Escobar MA; Levy JH; Tanaka KA
Haemophilia; 2010 May; 16(3):510-7. PubMed ID: 20050927
[TBL] [Abstract][Full Text] [Related]
16. In vivo bypass of hemophilia A coagulation defect by factor XIIa implant.
Ton-That TT; Doron D; Pollard BS; Bacher J; Pollard HB
Nat Biotechnol; 2000 Mar; 18(3):289-95. PubMed ID: 10700143
[TBL] [Abstract][Full Text] [Related]
17. The improved factor concentrate.
Lillicrap D
Hamostaseologie; 2009 Jan; 29(1):71-3. PubMed ID: 19151851
[TBL] [Abstract][Full Text] [Related]
18. Recent improvements in the clinical treatment of coagulation factor inhibitors.
Franchini M; Lippi G
Semin Thromb Hemost; 2009 Nov; 35(8):806-13. PubMed ID: 20169517
[TBL] [Abstract][Full Text] [Related]
19. [Clinical evaluation of factors VIII and IX manufactured in Hungary, based on results of the first half year].
Nemes L; Ceglédi A; Szabó G; Varga M; Sas G
Orv Hetil; 1998 Mar; 139(13):749-52. PubMed ID: 9578703
[TBL] [Abstract][Full Text] [Related]
20. Innovative coagulation factors: albumin fusion technology and recombinant single-chain factor VIII.
Schulte S
Thromb Res; 2013 Mar; 131 Suppl 2():S2-6. PubMed ID: 23537723
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]